Adaptin Bio (APTN) Long-Term Deferred Tax (2022 - 2023)
Adaptin Bio's (APTN) quarterly Long-Term Deferred Tax came in at $81335.0 in Q4 2023, up 192.53% year-over-year from $27804.0 in Q4 2022, and up 192.53% quarter-over-quarter from $27804.0 in Q4 2022.
Analysis
Adaptin Bio (APTN) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Adaptin Bio has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $81335.0 for Q4 2023.
- In Q4 2023, Long-Term Deferred Tax rose 192.53% year-over-year to $81335.0; the TTM figure through Dec 2023 stood at $81335.0 (up 192.53% YoY), while the FY2023 annual figure was $81335.0, up 192.53% from the prior year.
- Long-Term Deferred Tax came in at $81335.0 for Q4 2023 at Adaptin Bio, up from $27804.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $81335.0 in Q4 2023 to a low of $27804.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - |